Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Telomir Pharmaceuticals Inc (TELO)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.78-10.85%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for TELO yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Complete integration of TELI Pharmaceuticals | Telomir completed the acquisition of TELI Pharmaceuticals in April 2026. | Intact | Acquisition integration delays or failures reported in 2026 | Qualitative condition This condition has no defined numerical measure. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, speculative clinical-development story, not an established compounder. The long-term thesis is still insufficiently tested: management has advanced the Telomir-Zn program and completed the TELI acquisition, but the evidence snapshot offers little financial history.
Valuation evidence is thin, and the company is loss-making, so a conventional comparison with profitable peers is not supported. The snapshot does not show what expectations are already reflected in the valuation, leaving that part of the thesis unclear.
In the near term, the FDA clearance for Phase 1/2 trials in triple-negative breast cancer, the private placement, and peer-reviewed research mark progress on stated priorities. However, the recent equity issuance raises a capital-allocation concern, and the company remains loss-making with high risk and a 51% estimated chance of missing its next print. Over the multi-year view, clinical and scientific progress matters, but the evidence is too limited to establish a reliable financial trajectory.
The thesis hinges on whether clinical development produces credible progress and whether research findings translate into stronger evidence for Telomir-Zn. Near-term sector support could persist if major healthcare companies continue to report strong results, while weaker jobs data or disappointing sector results could remove that tailwind.
TELO has made concrete development and research progress, but its loss-making status, financing concerns, high risk, and limited financial history leave the 1- to 3-year thesis uncertain. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Management aims to resolve the delisting notice and enhance strategic partnerships. |
| Intact |
| Delisting notice unresolved or escalated beyond 2026 |
Qualitative condition This condition has no defined numerical measure. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Grow revenue to at least $1.5 million in 2026 | A primary condition in Telomir Pharmaceuticals Inc's published investment case. The stated target is >= $1.5 million revenue in FY26. | Intact | Revenue falls below $1.5 million in FY26 | Revenue: $0 FY2026-Q2; GAAP. Published target: >= $1.5 million revenue in FY26. Annual target cannot be compared with a quarterly or TTM observation. Aug 13, 20260 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Enhance strategic partnerships for R&D | Management aims to resolve the delisting notice and enhance strategic partnerships. | Improving | No new or expanded partnerships by end of 2026 | Qualitative condition This condition has no defined numerical measure. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.17 → $-0.17 · observed estimates
FY2027 revenue: comparable history unavailable.
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-09-18 | $-0.17 | Unavailable | 1 / 0 |
| 2026-09-19 | $-0.17 | Unavailable | 1 / 0 |
| 2026-09-20 | $-0.17 | Unavailable | 1 / 0 |
| 2026-09-21 | $-0.17 | Unavailable | 1 / 0 |
| 2026-09-22 | $-0.17 | Unavailable | 1 / 0 |
| 2026-09-23 | $-0.17 | Unavailable | 1 / 0 |
| 2026-09-24 | $-0.17 | Unavailable | 1 / 0 |
| 2026-09-25 | $-0.17 | Unavailable | 1 / 0 |
| 2026-09-26 | $-0.17 | Unavailable | 1 / 0 |
| 2026-09-27 | $-0.17 | Unavailable | 1 / 0 |
| 2026-09-28 | $-0.17 | Unavailable | 1 / 0 |
| 2026-09-29 | $-0.17 | Unavailable | 1 / 0 |
| 2026-09-30 | $-0.17 | Unavailable | 1 / 0 |
| 2026-10-01 | $-0.17 | Unavailable | 1 / 0 |
| 2026-10-02 | $-0.17 | Unavailable | 1 / 0 |
| 2026-10-03 | $-0.17 | Unavailable | 1 / 0 |
| 2026-10-04 | $-0.17 | Unavailable | 1 / 0 |
| 2026-10-05 | $-0.17 | Unavailable | 1 / 0 |
| 2026-10-06 | $-0.17 | Unavailable | 1 / 0 |
| 2026-10-07 | $-0.17 | Unavailable | 1 / 0 |
| 2026-10-08 | $-0.17 | Unavailable | 1 / 0 |
| 2026-10-09 | $-0.17 | Unavailable | 1 / 0 |
| 2026-10-10 | $-0.17 | Unavailable | 1 / 0 |
| 2026-10-11 | $-0.17 | Unavailable | 1 / 0 |
| 2026-10-12 | $-0.17 | Unavailable | 1 / 0 |
| 2026-10-13 | $-0.17 | Unavailable | 1 / 0 |
| 2026-10-14 | $-0.17 | Unavailable | 1 / 0 |
| 2026-10-15 | $-0.17 | Unavailable | 1 / 0 |
| 2026-10-16 | $-0.17 | Unavailable | 1 / 0 |
| 2026-10-17 | $-0.17 | Unavailable | 1 / 0 |
| 2026-10-18 | $-0.17 | Unavailable | 1 / 0 |
| 2026-10-19 | $-0.17 | Unavailable | 1 / 0 |
| 2026-10-20 | $-0.17 | Unavailable | 1 / 0 |
| 2026-10-21 | $-0.17 | Unavailable | 1 / 0 |
| 2026-10-22 | $-0.17 | Unavailable | 1 / 0 |
| 2026-10-23 | $-0.17 | Unavailable | 1 / 0 |
| 2026-10-24 | $-0.17 | Unavailable | 1 / 0 |
| 2026-10-25 | $-0.17 | Unavailable | 1 / 0 |
| 2026-10-26 | $-0.17 | Unavailable | 1 / 0 |
| 2026-10-27 | $-0.17 | Unavailable | 1 / 0 |
| 2026-10-28 | $-0.17 | Unavailable | 1 / 0 |
| 2026-10-29 | $-0.17 | Unavailable | 1 / 0 |
| 2026-10-30 | $-0.17 | Unavailable | 1 / 0 |
| 2026-10-31 | $-0.17 | Unavailable | 1 / 0 |
| 2026-11-01 | $-0.17 | Unavailable | 1 / 0 |
| 2026-11-02 | $-0.17 | Unavailable | 1 / 0 |
| 2026-11-03 | $-0.17 | Unavailable | 1 / 0 |
| 2026-11-04 | $-0.17 | Unavailable | 1 / 0 |
| 2026-11-05 | $-0.17 | Unavailable | 1 / 0 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.